Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Iovance Biotherapeutics Inc. diskutieren

Iovance Biotherapeutics Inc.

WKN: A2DT49 / Symbol: IOVA / Name: Iovance Biotherapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

7,48 €
1,00 %

Einschätzung Buy
Rendite (%) -48,50 %
Kursziel 19,38
Veränderung
Endet am 28.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -49,42 %
Kursziel 29,60
Veränderung
Endet am 28.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,08 %
Kursziel 29,70
Veränderung
Endet am 10.05.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -26,51 %
Kursziel 29,48
Veränderung
Endet am 24.05.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,47 %
Kursziel 29,48
Veränderung
Endet am 31.05.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat